Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-086311
Chunk: 7

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 7
---
 trajectory and realize our bright future. Our priorities in the coming year include:

| • |     | Expanding adoption of MIPLYFFA. We are actively focused on increasing awareness and adoption of MIPLYFFA.                                                                                                                                            
 Most recently, in February 2025, we launched efforts to provide integral educational and testing resources to NPC treatment teams and physicians in the U.S. Our market access team is also working tirelessly to continuously engage with payors to 
 formalize coverage so that all patients may have access to this life-changing treatment.                                                                                                                                                             |

| • |     | Securing regulatory approval of MIPLYFFA in the EU. We remain on track to file a marketing authorization                                                         
 application (MAA) in the second half of 2025. This approval would further expand our addressable market to the estimated 1,100 people living with NPC in the EU. |

| • |     | Expanding adoption of OLPRUVA for the adult-onset population for whom OLPRUVA’s portability and ease                                
 of administration may be most beneficial. Our efforts are also focused on supporting patients facing insurance coverage challenges. |

| • |     | Accelerating enrollment in the Phase 3 DiSCOVER trial for celiprolol, by expanding our outreach and                                                                                                                                                 
 education efforts within the patient community and among treating physicians. Accelerating enrollment and completion of the Phase 3 trial will advance efforts towards making this potential treatment available. There are currently no treatments 
 approved in the U.S. for VEDS and the approximately 7,500 people living with this disease.                                                                                                                                                          |

With a strong pipeline of innovative products, multiple upcoming milestones in the coming quarters, and your management team’s continued disciplined execution, we are confident that Zevra is positioned for long-term success. Your Board and Management Team Already Have Fresh Perspectives to Drive Stockholder Value The Zevra Board and management team have been dramatically refreshed since 2023. Seven out of the eight current directors joined the Board in the past two years.Since his appointment as President and CEO in October 2023, Mr. McFarlane’s leadership has delivered significant stockholder value creation. Since then, we have added more talent and expertise to support Zevra’s continued growth, as evidenced by our June 2024 executive appointments. Your Board is composed of directors who are exceptionally qualified, independent, and committed to acting in the best interests of all Zevra stockholders.They provide rigorous oversight of the Company’s progress, and we are confident they are